Antitumor Effect of Thymosin α1/Interleukin-2 or Thymosin α1/Interferon α,β Following Cyclophosphamide in Mice Injected with Highly Metastatic Friend Erythroleukemia Cells

Enrico Garaci, Francesca Pica, Antonio Mastino, Anna Teresa Palamara, Filippo Belardelli, Cartesio Favalli

Research output: Contribution to journalArticle

Abstract

We investigated the effects of the systemic administration of thymosin α1 plus relatively low doses of human recombinant interleukin-2 or very low doses of interferon α,β in untreated and cyclophosphamide (CY)-treated DBA/2 mice challenged either subcutaneously or intravenously (i.v.) with Friend erythroleukemia cells (FLC). Both treatments resulted in the complete regression of subcutaneous tumor and cured a significative percentage of mice. They also increased the survival time of mice i.v. injected with large numbers of FLC. Neither immunotherapy alone nor CY, alone or in combination with single cytokines, produced similar effects. The antitumor action of these combined chemoimmunotherapy protocols seems to involve activation of the immune response since (a) a synergistic increase of the cytotoxicity of spleen cells was demonstrated in treated mice; (b) selective in vivo depletion of asialo-GM1, CD4, or CD8-positive cells abrogated this antitumor activity; and (c) a high lymphoid cell infiltration was found at the tumor site and in the livers of treated mice.

Original languageEnglish
Pages (from-to)7-17
Number of pages11
JournalJournal of Immunotherapy
Volume13
Issue number1
Publication statusPublished - 1993

Keywords

  • Cyclophosphamide
  • Friend erythroleukemia cell tumor
  • Interferon
  • Interleukin-2
  • Thymosin α1

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Pharmacology

Fingerprint Dive into the research topics of 'Antitumor Effect of Thymosin α1/Interleukin-2 or Thymosin α1/Interferon α,β Following Cyclophosphamide in Mice Injected with Highly Metastatic Friend Erythroleukemia Cells'. Together they form a unique fingerprint.

  • Cite this